Apretude 200 mg

Apretude 200 mg is an extended-release suspension of cabotegravir for intramuscular use. It is designed for long-acting HIV prevention and treatment, offering a convenient alternative to daily oral medications.

Apretude 200 mg is primarily used for HIV pre-exposure prophylaxis (PrEP) and as part of a treatment regimen for HIV-1 infection. This extended-release suspension is administered intramuscularly, providing long-lasting protection and simplifying the medication routine for those at risk of HIV or managing the condition.

Common effects of Apretude 200 mg may include injection site reactions, such as pain, redness, or swelling. Some individuals might experience headaches, fever, or fatigue. These effects are generally mild and temporary, but any persistent or severe symptoms should be discussed with a healthcare provider.

Apretude 200 mg should be handled with care, ensuring proper storage and administration by a healthcare professional. It is important to disclose any allergies or medical conditions before use. Regular monitoring and follow-up appointments are recommended to ensure the medication's effectiveness and safety.

Apretude 200 mg may interact with certain medications, including those that affect liver enzymes, such as CYP3A inhibitors or inducers. It is crucial to inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions.